Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia 2Philadelphia Chromosome 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Muscle Weakness 1Multiple Myeloma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

blinatumomab 15Cyclophosphamide 15Cytarabine 14Azacitidine 11venetoclax 10fludarabine 10fludarabine phosphate 7Methotrexate 7Daunorubicin 7Rituximab 6Vincristine 5Mercaptopurine 5Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Dexamethasone 3Cladribine 3Busulfan 3Asparaginase 3thymoglobulin 2pembrolizumab 2pegaspargase 2nilotinib 2midostaurin 2daratumumab 2Vindesine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Magnetic Resonance Imaging × Other hematologic neoplasm × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡